دورية أكاديمية
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
| العنوان: | Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma |
|---|---|
| المؤلفون: | Mencoboni M., Filiberti R. A., Taveggia P., Grosso F., Pasello G., Del Corso L., Muzio A., Polo V., Zucali P., Ceresoli G. L., Soto Parra H. J., Auriati L., Simonassi C. |
| المساهمون: | Mencoboni, M., Filiberti, R. A., Taveggia, P., Grosso, F., Pasello, G., Del Corso, L., Muzio, A., Polo, V., Zucali, P., Ceresoli, G. L., Soto Parra, H. J., Auriati, L., Simonassi, C. |
| بيانات النشر: | S. Karger AG |
| سنة النشر: | 2017 |
| المجموعة: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| مصطلحات موضوعية: | Chemotherapy, Malignant pleural mesothelioma, Response, Surgery, Survival, Adult, Age Distribution, Aged, 80 and over, Female, Human, Italy, Longitudinal Studie, Male, Mesothelioma, Middle Aged, Pleural Neoplasm, Prevalence, Prognosi, Retrospective Studie, Risk Factor, Sex Distribution, Survival Rate, Treatment Outcome |
| الوصف: | Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/28472807; info:eu-repo/semantics/altIdentifier/wos/WOS:000403363900013; volume:40; issue:6; firstpage:364; lastpage:369; numberofpages:6; journal:ONCOLOGY RESEARCH AND TREATMENT; http://hdl.handle.net/11577/3368080Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85018935573 |
| DOI: | 10.1159/000464410 |
| الإتاحة: | https://doi.org/10.1159/000464410Test http://hdl.handle.net/11577/3368080Test |
| رقم الانضمام: | edsbas.7AA9C56 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1159/000464410 |
|---|